0
Tech & Innovation·August 29, 2026·1 min read

Trade unions threaten to withhold support for politicians opposing data center projects, warning that blocking the projects endangers building-related jobs

Share

Data centers are now a labor issue as much as a land-and-power issue—unions tying political support to approvals will make outright moratoria harder to sustain. If you're siting or expanding facilities, factor organized labor and local jobs narratives into your permitting and community strategy, not just tax incentives.

Tech & Innovation

Texas, which didn't join a multi-state case against Meta, negotiated a $1.05B side deal that could reach $1.335B if TikTok and YouTube adopt teen safety changes

Texas extracting a $1.05B–$1.335B side deal tied to teen safety changes on Meta, TikTok, and YouTube shows states are willing to run their own monetized regulatory tracks. If you operate a youth-facing product, assume state-by-state negotiations and compliance carve-outs are now on the table—not just federal or multi-state settlements—and budget legal and policy capacity accordingly.

Tech & Innovation

The new reMarkable Paper Pure wowed us with its 'flawless' pad-and-pen experience, but it's far from the only great handwriting tablet on the market — here are our top alternatives

E-ink tablets are now a mature, crowded category—your differentiation as a vendor or integrator is in workflow integration, not hardware feel. If you're standardizing devices for teams, optimize for sync, export, and security policies across tools rather than chasing marginally better handwriting experiences.

Tech & Innovation

Google says the Pixel Watch 5 can beat Apple and Garmin for GPS accuracy — so I decided to test all three watches myself on the London Marathon course

Wearables are competing on sensor fidelity, not just apps—route accuracy over 26.2 miles is a proxy for how much you can trust the data in your health or fitness stack. If you’re building on consumer telemetry, vendor choice now directly affects model quality and compliance claims around “clinical-grade” insights.